Research Advances and Therapeutic Strategies (RATS) in Cardio-Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 May 2026 | Viewed by 78
Special Issue Editors
2. Cardio-Oncology Program, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
Interests: cardio-oncology; cardio–kidney–metabolic syndrome; health disparities; proteomics; artificial intelligence
2. Cardio-Oncology Program, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
Interests: cardio-oncology; artificial intelligence; proteomics; health disparities; cardio–kidney–metabolic syndrome
2. Cardio-Oncology Program, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
Interests: cardio-oncology; health disparities; cardio–kidney–metabolic syndrome; artificial intelligence; proteomics
Special Issue Information
Dear Colleagues,
Advances in oncology have improved cancer survivorship; however, they have also revealed a spectrum of treatment-related cardiovascular complications—from anthracycline-induced cardiomyopathy and radiation-mediated vascular injury to immune checkpoint inhibitor myocarditis and targeted-therapy arrhythmias. Emerging research has uncovered the mechanisms driving these toxicities, including oxidative stress, endothelial dysfunction, immune dysregulation, and genetic susceptibility.
Simultaneously, progress in imaging, biomarkers, and AI-driven models has refined our ability to stratify risk and detect subclinical injury. Multidisciplinary teams, with a focus on health equity, are essential to translating these tools into practice. However, we still lack cancer-specific risk scores, cardioprotective trials, and comprehensive guidelines for novel agents and long-term survivorship care.
We invite submissions encompassing studies that elucidate the molecular and genetic drivers of therapy-related cardiotoxicity; investigations that validate advanced imaging modalities, circulating biomarkers, digital health platforms, and AI-driven tools for early detection and seamless collaboration between oncology and cardiology teams; evaluations of novel cardioprotective strategies—whether pharmacologic, lifestyle-based, or device-oriented; the development of practical risk stratification frameworks and implementable care pathways tailored to oncology populations; and analyses that address health disparities and real-world cardiovascular outcomes across diverse cancer survivor cohorts.
Through a collaborative scientific inquiry, we aim to improve cardiovascular outcomes for patients facing the challenges of both cancer and heart disease. We look forward to your contributions.
Dr. Avirup Guha
Guest Editor
Dr. Viraj Shah
Dr. Tarek Nahle
Guest Editor Assistants
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiotoxicity
- artificial intelligence
- multi-omics
- cardiac toxicities
- surveillance
- cardioprotective agents
- multimodal imaging
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
